Hormonal contraception, as a class, can be used to correct menstrual abnormalities, increase predictability and reduce blood loss, among other benefits.
Consider hormonal contraception to address the following:
Excessive menstrual bleeding
PMDD / PMS
Combined oral contraceptives (OCs) only – 30 mcg ethinyl estradiol, drospirenone
Menstrual migraines without focal neurologic signs, nonsmokers, under 35 years of age
Extended cycle or continuous hormone contraception
Combined OCs only
Ring, patch and progestin-only as methods are less effective
Control of menstrual bleeding is a significant benefit of hormonal contraception methods. In addition, OC users have a 50% reduction in risk of endometrial cancer, a benefit that persists for up to 20 years after use. The levonorgestrel intrauterine system effectively treats endometrial hyperplasia without atypia; however, data are limited in its role in hyperplasia with atypia. Reduction in risk of ovarian cancer parallels the duration of combined OC use, with a decrease of about 20% for every 5 years of use. Recent, but not past, use of OCs appears to lower risk of colorectal cancer.
Hormonal contraception probably has no role in the following:
Prevention/treatment of follicular or corpus luteum cysts
Prevention/treatment of osteopenia or osteoporosis
Prevention of the development of leiomyomas
Bone loss during contraceptive use is likely analogous to that which occurs with breastfeeding and is rapidly reversed
Past users of DPMA and progestin implants have similar bone densities to non-users
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan